NICE TA281: for treating gouty arthritis attacks and reducing the frequency of subsequent attacks. (Terminated appraisal). (Decision date - May 2013).
NICE TA302: for treating systemic juvenile idiopathic arthritis. (Decision date - December 2013).
NHSE Clinical Commissioning Policy SSC2437: Canakinumab for patients
with Still’s disease refractory to anakinra and tocilizumab (adults and
children 2 years and over)- The policy confirms that canakinumab is not
routinely commissioned for these patients. (Decision date - November 2022).
Do Not Prescribe (DNP) Drug Classifications
6: Have NICE guidance that recommends they should not be used
